UMGCCC neuro-oncologist navigates the reality of his father’s pancreatic cancer https://cancerletter.com/guest-editorial/20260522_5/

"When my father has pain at 2:00 AM: Do we wait or call the patient assistance line? It has humbled my perspective; now see the paralyzing indecision that happens long before my patients reach the office." Guest editorial by Haroon Ahmad, MD https://cancerletter.com/guest-editorial/20260522_5/

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment https://cancerletter.com/clinical-roundup/20260522_9a/

USPSTF leaders John Wong and Esa Davis fired by Kennedy, leaving the panel rudderless https://cancerletter.com/regulatory-news/20260522_4/

NCI’s Letai gets softball questions from Senate appropriators at an otherwise contentious hearing https://cancerletter.com/nci/20260522_3/

Charles Rudin named cancer center director at @mskcancercenter.bsky.social https://cancerletter.com/in-brief/20260522_7a/

FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure https://cancerletter.com/cancer-policy/20260522_6a/

Marcel van den Brink: Microbiome research is now in “critical phase” where evidence points to therapeutic use @cityofhope.bsky.social https://cancerletter.com/conversation-with-the-cancer-letter/20260522_2/

Kennedy calls for a “moonshot” focused on the role of the microbiome in cancer @cityofhope.bsky.social https://cancerletter.com/the-cancer-letter/20260522_1/

“After years of recognizing the dangers flavored e-cigarettes pose to youth, it is deeply troubling to see FDA ignore the scientific evidence and reverse course,” said Harold Wimmer, American Lung Association President and CEO. https://cancerletter.com/regulatory-news/20260515_2/

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials https://cancerletter.com/in-brief/20260515_7d/

Cedars-Sinai leads development of AI-based tool to predict spatial gene expression in tumors https://cancerletter.com/clinical-roundup/20260515_9b/

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer. @stjuderesearch.bsky.social https://cancerletter.com/podcastc/20260515_1/

As long-time leaders, Sherr and Evans were a part of the institution’s rise and thus speak authoritatively about the institutional culture, leadership philosophy, and scientific ambition that shaped St. Jude. (@stjuderesearch.bsky.social) https://cancerletter.com/podcastc/20260515_1/

FDA grants Fast Track designation to Suplexa in MSI-H CRC https://cancerletter.com/drugs-and-targets/20260515_10d/

In a letter to President Trump, bopharma leaders are urging that Pazdur, FDA’s long-time oncology leader, be appointed commissioner, replacing Makary. https://cancerletter.com/regulatory-news/20260515_3/

Ovarian Cancer Research Alliance launches a global AI-powered ecosystem to accelerate gynecologic cancer research https://cancerletter.com/in-brief/20260515_7c/

Stage 4 breast cancer has increased in incidence and proportion over the last decade https://cancerletter.com/clinical-roundup/20260515_9a/

How City of Hope is turning microbiome science into better cancer care. Guest editorial by Marcel van den Brink, MD, PhD and Robert Jenq, MD (@cityofhope.bsky.social) https://cancerletter.com/sponsored-article/20260515_4/

@theaacr.bsky.social opens four funding opportunities https://cancerletter.com/funding-opportunities/20260515_8a/

FDA clears AI digital pathology risk stratification tool in breast cancer https://cancerletter.com/drugs-and-targets/20260515_10c/

In a recent set of regulatory decisions that culminated in the resignation of FDA Commissioner Marty Makary on May 12, the agency appears to have reversed its hard-ball stance on flavored e-cigarettes. https://cancerletter.com/regulatory-news/20260515_2/

The immediate impetus for FDA Commissioner Marty Makary’s exit from the top job at FDA is arguably less significant than the legacy of dysfunction he leaves behind. https://cancerletter.com/regulatory-news/20260515_3/

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program https://cancerletter.com/drugs-and-targets/20260515_10b/

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response (@stanfordmedicine.bsky.social) https://cancerletter.com/clinical-roundup/20260508_8d/

DoD awards $8M to five institutions to improve care for glioblastoma patients (@uclaupdates.bsky.social, @duke-university.bsky.social, @ucsfhealth.bsky.social, @mskcancercenter.bsky.social, @mdanderson.bsky.social) https://cancerletter.com/in-brief/20260515_7b/

ACCC and cancer community partners issue statement on U.S. drug shortages, urge action https://cancerletter.com/cancer-policy/20260515_6b/

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML https://cancerletter.com/drugs-and-targets/20260515_10a/

After a year-long reign over tumult at FDA, Makary heads for the exit Fruit-flavored e-cigs were the final blow for the commissioner https://cancerletter.com/regulatory-news/20260515_3/

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer. Guest editorial by Dr. Dan Duda, PhD. (@houstonmethodist.bsky.social) https://cancerletter.com/sponsored-article/20260515_5/

"Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital (@stjuderesearch.bsky.social) https://cancerletter.com/cancer-history-project/20260515_1/

California Spectrum 1 profiles Steven Rosen, an oncologist-poet (@cityofhope.bsky.social) https://cancerletter.com/in-brief/20260515_7a/

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions https://cancerletter.com/cancer-policy/20260515_6a/

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market https://cancerletter.com/regulatory-news/20260515_2/

Hopkins physicians achieve 95% cure rate for sickle cell disease with bone marrow transplant https://cancerletter.com/clinical-roundup/20260508_8c/

“ctDNA is already shaping clinical trials and practice, and we need clearer guidance on how to act on molecular progression in metastatic cancer because the field has already begun to move." - Neil Vasan, MD, of NYU Langone Health https://cancerletter.com/regulatory-news/20260508_1/

Thomas Buchholz receives the American Radium Society’s Gold Medal Award https://cancerletter.com/in-brief/20260508_6d/

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds https://cancerletter.com/clinical-roundup/20260508_8b/

At the [FDA] meeting, ODAC members were asked to vote Yes or No on whether switching to camizestrant following biomarker-based progression like in SERENA-6 would benefit these patients. https://cancerletter.com/regulatory-news/20260508_1/

Joyce Ohm: Of "the handful of scientific advances that have kind of been super-accelerators over the last 100 years, this is one of them. Would it have gotten done eventually? Sure. But Dr. Venter definitely made this go faster." (@jcvi.org) https://cancerletter.com/letter-to-the-editor/20260508_3/

@americancancersoc.bsky.social names four members to Board of Directors https://cancerletter.com/in-brief/20260508_6c/

FDA’s OCE announces funding opportunity in ultra-rare cancers https://cancerletter.com/funding-opportunities/20260508_7a/

J. Craig Venter, a scientist and entrepreneur who raced against the Human Genome Project to decode the human genome, died on April 29, 2026. He was 79. (@jcvi.org) https://cancerletter.com/letter-to-the-editor/20260508_3/

FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease https://cancerletter.com/drugs-and-targets/20260508_9b/

American College of Radiology approves first ever Practice Parameter for Imaging Artificial Intelligence https://cancerletter.com/clinical-roundup/20260508_8a/

AstraZeneca’s application for camizestrant, a next-generation oral selective estrogen receptor degrader, or SERD, in metastatic breast cancer might have seemed set to sail smoothly through the FDA approval process. https://cancerletter.com/regulatory-news/20260508_1/

Amelia Jernigan named cancer service line director for LCMC Health https://cancerletter.com/in-brief/20260508_6b/

Katherine Szarama steps in as CBER acting director, replacing Prasad https://cancerletter.com/cancer-policy/20260508_5b/

FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib https://cancerletter.com/drugs-and-targets/20260508_9a/

Collaborative work behind the scenes makes cancer breakthroughs possible. Guest editorial by Anna Daniels.(@ascocancer.bsky.social) https://cancerletter.com/sponsored-article/20260508_4/